

**Amendments to the Claims:**

1. (Currently amended) A method for treating pain in a patient in need thereof comprising administering to the patient an amount of ~~substantially enantiomerically pure~~ (S)-norketamine or a pharmaceutically acceptable salt or solvate thereof, which falls in the range of about 0.01 to about 820 mg/kg of body weight of the patient and which, as determined by a physician or medical care provider, is effective to treat pain while not inducing dysphoria.

2. (Currently amended) The method of claim 1 in which ~~substantially enantiomerically pure~~ (S)-norketamine is administered to the patient.

3-4. (Canceled)

5. (Previously presented) The method of claim 1 in which the amount administered falls in a range of about 1% to about 50% of an amount used to induced anesthesia.

6. (Previously presented) The method of claim 1 in which the amount administered falls in a range of about 5% to about 40% of an amount used to induced anesthesia.

7. (Previously presented) The method of claim 1 in which the amount administered falls in a range of about 10% to about 20% of an amount used to induced anesthesia.

8. (Canceled)

9. (Previously presented) The method of claim 1 in which the amount administered falls in a range of about 0.05 to about 8 mg/kg of body weight of the patient.

10. (Currently amended) The method of claim 1 in which a pharmaceutically acceptable salt of ~~substantially enantiomerically pure~~ (S)-noreketamine (S)-norketamine is administered to the patient.

11-12. (Canceled)

13. (Previously presented) The method of claim 1 in which the amount is administered over a 24 hour period.

14. (Previously presented) The method of claim 1 in which the amount is administered in conjunction with a narcotic analgesic effective to alleviate pain.

15. (Currently amended) The method of claim 1, further comprising decreasing a dose of ~~the~~ a narcotic analgesic.

16. (Currently amended) A method for self-treating pain in a subject comprising self-administering on an outpatient basis via one or more routes selected from a transmucosal, transdermal, nasal, oral, rectal, vaginal, ocular, or pulmonary route, or any combination of the foregoing routes, an amount of substantially enantiomerically pure (S)-norketamine, or a pharmaceutically acceptable salt or solvate thereof, which falls in the range of about 0.01 to about 820 mg/kg of body weight of the patient and which, as determined by a physician or medical care provider, is effective to treat pain while not inducing dysphoria.

17. (Previously presented) The method of claim 16 in which the route of administration is oral.

18-27. (Canceled)

28. (Previously presented) The method of claim 16 in which said pain is selected from the group consisting of breakthrough pain, pain associated with wind-up, chronic pain and neuropathic pain.

29-70. (Canceled)

71. (Previously presented) The method of claim 1 in which the amount is administered to the patient via a route selected from the group consisting of intravenous, intramuscular, subcutaneous, intrathecal, and epidural.

72. (Canceled)

73. (Withdrawn- currently amended) A method for treating breakthrough pain in a patient in need thereof comprising administering to the patient an amount of substantially

~~enantiomerically pure~~ (S)-norketamine or a pharmaceutically acceptable salt or solvate thereof, which, as determined by a physician or medical care provider, is effective to treat breakthrough pain while not inducing dysphoria.

74. (Withdrawn) The method of claim 73 which further comprises administering a narcotic analgesic.

75. (Withdrawn) The method of claim 73 in which the amount is administered orally.

76. (Withdrawn) The method of claim 73 in which the amount administered falls in the range of about 0.01 to about 20 mg/kg of body weight of the patient.

77. (Withdrawn) The method of claim 73 in which the amount administered falls in the range of about 0.05 to about 8 mg/kg of body weight of the patient.

78. (Withdrawn-- currently amended) A method for treating pain associated with wind-up in a patient in need thereof comprising administering to the patient an amount of ~~substantially enantiomerically pure~~ (S)-norketamine or a pharmaceutically acceptable salt or solvate thereof, which, as determined by a physician or medical care provider, is effective to treat pain associated with wind-up while not inducing dysphoria.

79. (Withdrawn-- currently amended) A method for treating chronic pain in a patient in need thereof comprising administering to the patient an amount of ~~substantially enantiomerically pure~~ (S)-norketamine or a pharmaceutically acceptable salt or solvate thereof, which, as determined by a physician or medical care provider, is effective to treat chronic pain ~~up~~ while not inducing dysphoria.

80. (Currently amended) A method for treating neuropathic pain in a patient in need thereof comprising administering to the patient an amount of ~~substantially enantiomerically pure~~ (S)-norketamine or a pharmaceutically acceptable salt or solvate thereof, which, as determined by a physician or medical care provider, is effective to treat neuropathic pain ~~up~~ while not inducing dysphoria.

81. (Withdrawn– currently amended) An oral dosage form comprising ~~substantially enantiomerically pure~~ (S)-norketamine or a pharmaceutically acceptable salt or solvate thereof and one or more pharmaceutically acceptable excipients, which dosage form, when self-administered in an amount falling in the range of about 0.01 mg/kg to about 20 mg/kg of body weight of the patient, is effective, as determined by a physician or medical care provider, to treat pain while not inducing dysphoria.

82. (Withdrawn– currently amended) The oral dosage form of claim 81 which comprises ~~substantially enantiomerically pure~~ (S)-norketamine.

83. (Withdrawn– currently amended) The oral dosage form of claim 81 which comprises a pharmaceutically acceptable salt of ~~substantially enantiomerically pure~~ (S)-norketamine.

84. (New) A method for treating pain in a patient in need thereof comprising administering orally to the patient an amount of (S)-norketamine or a pharmaceutically acceptable salt or solvate thereof, which falls in the range of about 0.01 to about 8 mg/kg of body weight of the patient and which, as determined by a physician or medical care provider, is effective to treat pain while not inducing dysphoria.

85. (New) The method of claim 84 in which the amount administered orally falls in the range of about 0.05 to about 8 mg/kg of body weight of the patient.